A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

BACKGROUND: High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a larger proportion of patients. However, not all patients respond to immune checkpoint b...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchbinder, Elizabeth I., Gunturi, Anasuya, Perritt, Jessica, Dutcher, Janice, Aung, Sandra, Kaufman, Howard L., Ernstoff, Marc S., Miletello, Girald P., Curti, Brendan D., Daniels, Gregory A., Patel, Sapna P., Kirkwood, John M., Hallmeyer, Sigrun, Clark, Joseph I., Gonzalez, Rene, Richart, John M., Lutzky, Joe, Morse, Michael A., Sullivan, Ryan J., McDermott, David F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028986/
https://www.ncbi.nlm.nih.gov/pubmed/27660706
http://dx.doi.org/10.1186/s40425-016-0155-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028986/
https://www.ncbi.nlm.nih.gov/pubmed/27660706
http://dx.doi.org/10.1186/s40425-016-0155-8

Ejemplares similares